- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Masonic Cancer Center, University of Minnesota | Strategic Alliance Partners
The Masonic Cancer Center, University of Minnesota, is the Twin Cities’ only Comprehensive Cancer Center, designated ‘Outstanding’ by the National Cancer Institute. As Minnesota’s Cancer Center, we have served the entire state for more than 30 years. Our researchers, educators, and care providers work to discover the causes, prevention, detection, and treatment of cancer and cancer-related diseases as well as provide whole-of-life care and resources for survivorship. Learn more at cancer.umn.edu
Connect with us:
Latest from Masonic Cancer Center, University of Minnesota
Dr Miller on the Use of NK Cell Therapy in Hematologic Malignancies
August 16, 2024
Video
Jeffrey S. Miller, MD, discusses research with natural killer cell therapy in patients with hematologic malignancies and other cancers.
Dr Yee on Neoadjuvant Datopotamab Deruxtecan in High-Risk, Early-Stage Breast Cancer
August 13, 2024
Video
Douglas Yee, MD, discusses neoadjuvant datopotamab deruxtecan in early-stage breast cancer
Dr Eckfeldt on the Implications of Improved MRD Testing in AML
July 19, 2024
Video
Craig Eckfeldt, MD, PhD, discusses how improved minimal residual disease testing methods have impacted the acute myeloid leukemia treatment paradigm.
Dr Juckett on the Evolving Treatment Paradigm in Relapsed/Refractory AML
July 18, 2024
Video
Mark Juckett, MD, discusses ways the treatment paradigm has changed for patients with relapsed/refractory acute myeloid leukemia.
Dr Maakaron on Choosing Between Bispecific Antibodies and CAR T-Cell Therapy in DLBCL
June 27, 2024
Video
Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.
Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCL
June 27, 2024
Video
Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.
CAR T-Cell Therapy vs Bispecific Antibodies: Picking an Approach in R/R DLBCL
June 13, 2024
Article
Marie Hu, MD, discusses considerations for the use of CAR T-cell therapy and bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma.
Recent Data Shed Further Light on the MDS Treatment Paradigm as the SOC Evolves
May 30, 2024
Article
Jeremy Allred, MD, details current and emerging treatments for patients with myelodysplastic syndrome, highlighting recent key data updates.
Desai Details Efforts Exploring Treatment Strategies in CLL Post–BTK Inhibitor Progression
May 28, 2024
Article
Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia.
Genetic Information and Patient Factors Influence BTK Inhibitor Sequencing in Frontline CLL and Beyond
May 24, 2024
Article
Sanjal Desai, MD, expands on the safety, efficacy, and sequencing of BTK inhibitors and venetoclax-based regimens in chronic lymphocytic leukemia.
Eckfeldt Looks Towards the Future of AML and MDS Care
May 22, 2024
Article
Craig Eckfeldt, MD, PhD, discusses key updates in the MDS treatment paradigm and the implications of MRD testing, as well as next steps in the field of AML.
Prognostic Study Correlates TSP and Clinical Outcomes in High-Grade Serous Ovarian Cancer
May 17, 2024
Article
TSP is a reliable marker of clinical outcome measures, including platinum chemoresistance, PFS, and OS, in high-grade serous ovarian cancer.
Dr Lou on the Predictive and Prognostic Utility of Tumor Stroma Proportion in Ovarian Cancer
May 15, 2024
Video
Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic value of tumor stroma proportion for survival outcomes in ovarian cancer.
Dr Antonarakis on Community Enrollment in the ECLIPSE Trial in Prostate Cancer
March 29, 2024
Video
Emmanuel Antonarakis, MD, discusses community enrollment in the ECLIPSE trial in prostate cancer.
Drs Jha and Antonarakis on Collaboration Between Community and Academic Oncologists
March 29, 2024
Video
Gautam Jha, MD, and Emmanuel Antonarakis, MD, on the advantages of collaborative efforts between community and academic oncologists.
Dr Antonarakis on Early Intervention With PARP Inhibitors in mHSPC
March 20, 2024
Video
Emmanuel Antonarakis, MD, discusses the significance of TALPRO-3, EVOPAR, and AMPLITUDE trials on the metastatic prostate cancer treatment paradigm.
Community/Academic Research Collaboration Paves the Way for Improved Cancer Care
March 11, 2024
Article
Gautam Jha, MD, and Emmanuel Antonarakis, MD, discuss the ins and outs of clinical trial partnerships between community and academic cancer centers.
Community-Based Clinical Trial Enrollment Expands Access to Prostate Cancer Care
March 06, 2024
Article
Gautam Jha, MD, and Emmanuel Antonarakis, MD, discuss enrollment to the ECLIPSE trial in community and academic cancer center settings.
Outreach and Engagement: Colleagues Come Together to Improve Community Care
January 29, 2024
Article
Kiara Ellis, MSW, details community outreach and engagement conversations centered around key matters affecting NCI-designated cancer centers.
Dr. Bachanova on NK Cell Therapy in NHL
March 22, 2023
Video
Veronika Bachanova, MD, PhD, discusses findings from a spatial analysis of the tumor microenvironment in patients with non-Hodgkin lymphoma who received and responded to adoptive natural killer cell therapy.